A case of complete recovery in a hypereosinophilic dermatitis patient with dupilumab

Jiang, Xiaoyun; Ye, Jun; Wu, Xia; Zhu, Jiang; Chen, Siji; Cheng, Hao

doi:10.1007/s00011-023-01715-1

Cited by 4 publications

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is consistent with two subsequent reports on idiopathic HES (171,172). Isolated observations also support the effectiveness of dupilumab in idiopathic HES, however larger studies are needed to define its placing, if any (173,174).…”

Section: Wells Syndrome (Level Of Evidence 3a-4)supporting

confidence: 90%

Neutrophilic and eosinophilic dermatoses associated with hematological malignancy

Maronese,

Derlino,

Moltrasio

et al. 2024

Front. Med.

View full text Add to dashboard Cite

Cutaneous manifestations of hematologic malignancy represent both a clinical challenge for the treating physician and a pathophysiological model for advancing the knowledge on individual neoplasms. Indeed, a growing body of evidence supports the concept of recurrent molecular defects associating with specific clinical features, as best exemplified by VEXAS. Herein neutrophilic and eosinophilic dermatoses of potential interest for both hematologists and dermatologists will be reviewed, including subcorneal pustular dermatosis-type IgA pemphigus, neutrophilic eccrine hidradenitis, Sweet’s syndrome as well as myelodysplasia cutis and VEXAS, pyoderma gangrenosum, eosinophilic annular erythema, eosinophilic dermatosis of hematological malignancy, Wells syndrome and cutaneous involvement in hypereosinophilic syndromes. Possible management approaches are discussed for each, emphasizing scenarios that require treatment of the underlying condition to achieve remission at the skin level.

show abstract